CLL1 CAR-T

Conventional CLL1 CAR-T refers to a class of chimeric antigen receptor (CAR) T-cell therapies designed to target the C-type lectin-like molecule 1 (CLL1, also known as CLEC12A). CLL1 is a type II transmembrane glycoprotein that is highly expressed on the surface of acute myeloid leukemia (AML) blasts and leukemic stem cells, while being absent on normal hematopoietic stem cells. This expression profile makes it an attractive target for reducing off-tumor toxicity in AML treatment. In research and clinical contexts, "conventional" typically distinguishes standard CAR-T designs (often autologous or non-sequestered) from novel platforms that incorporate additional modifications, such as intracellular retention of TCR/CD3 (e.g., ThisCART) or gene editing to prevent graft-versus-host disease (GvHD). These therapies involve engineering T cells to express a CAR that recognizes CLL1, leading to targeted lysis of AML cells.

Other names

CLL1-directed CAR-TCLL-1-directed CAR-TCLL 1-directed CAR-TCLEC12A CAR-TCLEC-12A CAR-TCLEC 12A CAR-TC-type lectin-like molecule 1 CAR-TConventional CLL1 CAR-T